home / stock / ikna / ikna message board
Subject | By | Source | When |
---|---|---|---|
The now | Tartiaboy | investorshub | 05/10/2023 1:10:35 PM |
news all the way baby | crudeoil24 | investorshub | 05/05/2023 2:17:28 PM |
what do you make of this data? | crudeoil24 | investorshub | 04/17/2023 10:13:37 PM |
This is a very inactive board, but IKNA | Tartiaboy | investorshub | 01/29/2023 5:40:26 PM |
znewcar1: IKNA 29% v3,46M c5.37 f36,1M H5.37 EOD pop | znewcar1 | investorshangout | 06/25/2022 2:51:38 AM |
$IKNA look at this beast | TrendTrade2016 | investorshub | 05/06/2022 3:25:43 PM |
IKNA monster | TrendTrade2016 | investorshub | 05/06/2022 3:17:49 PM |
Ikena Oncology, Inc. is a targeted oncology company. | crudeoil24 | investorshub | 03/26/2021 3:56:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...